Egypt has witnessed a medical breakthrough as Ain Shams University launches a new drug for the treatment of cystic fibrosis, according to recent reports. The drug, known as Trikafta, was introduced for the first time in Egypt during a ceremony attended by high-ranking officials, including the Deputy Prime Minister and Minister of Health, Khaled Abdel Ghaffar, and the Minister of Higher Education and Scientific Research, Ayman Ashour. The launch event also included the signing of a cooperation protocol between the Faculty of Medicine at Ain Shams University and the Faculty of Medicine at Zagazig University in the field of organ transplantation.
The new genetic therapy represents a significant advancement in treating cystic fibrosis, a condition that affects thousands of patients worldwide by correcting a previously untreatable genetic mutation. This development opens promising avenues for patients who had no effective medical options before, offering hope for improved management of the disease through innovative gene-based treatment approaches.
The introduction of Trikafta in Egypt marks a milestone in the country’s healthcare capabilities, aligning with broader efforts to expand access to advanced therapies for rare genetic disorders. Medical professionals emphasize that such innovations are critical for addressing unmet medical needs in underserved populations.
